Organon launches its first Wellness Month initiative
August 1, 2021 11:48 am EDT
Women’s healthcare company Organon kicks off its global Organon Wellness Month in August, and the Australian subsidiary is making the most of the opportunity with a comprehensive program to promote employee health and wellbeing.
The month-long program aims to increase awareness and facilitate employee engagement focused on four pillars of wellness: physical; mental; professional; and social.
Based on these four pillars, Organon will reward employees who participate in the various programs offered, which include personalised health and wellness assessments; increase their daily physical activities; practice meditation techniques; or making time to develop and share hobbies. Reward incentives to further prompt employee engagement include fitness and massage vouchers. This initiative is complimented with a previously established $250 Wellness Reimbursement Program which can be used to pay for a wide range of wellbeing programs and equipment.
With COVID-19 impacting the work, home and school environment, Organon has increased its focus on workplace flexibility and initiatives to foster a more sustainable working environment which includes encouraging all employees to take time during the workday to focus on their health as well as that of their family and community.
“Through this commitment and various initiatives that our people can choose from, we recognise and respect the diversity of each person’s needs. We believe that our employees will emerge from this period feeling more energised and with some fuel in the tank, versus being totally exhausted with no annual leave left. We just think that this is a more sustainable approach, ” said Nirelle Tolstoshev, managing director Organon ANZ.
Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA
This news release of Organon & Co. (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).
Copyright © (2021) Organon group of companies. All rights reserved.
Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110002. First issued June 2021.